levels amyloid sapp beta blood cerebrospinal fluid brain dose dependent manner signs toxicity treatment months rats months monkeys obvious effect reduced fur pigmentation mice rabbits not seen monkeys researchers moved small early stage human trials assess safety tolerability inform choice suitable doses later trials verubecestat reduced amyloid sapp beta cerebrospinal fluid healthy adults took drug weeks patients mild moderate alzheimer took week detailed report bace inhibitor humans says dennis selkoe harvard university leading alzheimer researcher not involved work good news not evidence far effects concerned bace inhibition probably doses not fully inhibit bace1 activity vassar says need little bit bace